Oxfendazole in Mild Parenchymal Brain Cysticercosis

The goal of this clinical trial is to compare a single and multiple dose regimens of oxfendazole with the standard treatment in patients with mild (one or two lesions) parenchymal brain cysticercosis. The main question it aims to answer is if OXF will enhance clearance of brain parasites and therefore provide greater cysticidal efficacy, with the potential to provide a single-dose therapy for this type of NCC. The study cohort will also allow us to identify early imaging markers that predict lesion resolution, as well as factors associated with residual calcification or focal gliosis after lesion resolution. This study will also provide additional information on the safety of the study interventions.

NCT Number	NCT06565507
Lead Sponsor	Universidad Peruana Cayetano Heredia Collaborators: Oxfendazole Development Group
Conditions	Brain Cysticercosis
Enrollment	544 participants
Start Date	2026-12-01
Primary Completion	2030-03-15 (estimated)
Study Completion	2030-12-15 (estimated)
Updated on ClinicalTrials.gov	2026-05-01